angiotensin receptor blocker

Angiotensin receptor blockers tackle the same blood-pressure hormone as ACE inhibitors, but at a different point. Instead of stopping angiotensin II from being made, they let it form and then block the doors it needs to act on — the AT1 receptors on blood vessels — so the hormone arrives but cannot tighten the vessels.

The result is much the same: vessels relax, blood pressure falls, and the heart faces less resistance. Their generic names end in “-sartan,” and they are used for high blood pressure, heart failure, and kidney protection in diabetes, much like ACE inhibitors.

Their main practical advantage is that they do not cause the dry cough linked to ACE inhibitors, because they do not raise bradykinin. That makes them the standard alternative for people who cannot tolerate that cough, while delivering comparable cardiovascular benefit.

They share the other cautions of blocking this hormone system: they can raise potassium and affect kidney function, are generally not combined with an ACE inhibitor because of added risk, and must be avoided in pregnancy.